ReviewDiabetes, obesity & metabolism2022
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.
Review in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- HbA1c variability and risk of incident heart failure: A systematic review and meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- A digital-health multidomain lifestyle management framework and its associations with cardiometabolic health: a real-world observational study.BMC medicine · 2026Observational
- Review
- In-Hospital Glycemic Variability and Mean Blood Glucose as Risk Markers for Long-Term Mortality in Patients with Diabetes.Journal of clinical medicine · 2025Article
- Cardiometabolic Biomarkers and Cardiovascular Risk Stratification in Polish Military Personnel: A Chemometric Approach.International journal of molecular sciences · 2025Article
- Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden.European journal of medical research · 2025Article
- Continuous Glucose Monitoring Systems Can Meet the Challenge of Glucose Management and Beyond in Individuals with Type 2 Diabetes: An Expert Multidisciplinary Position.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Hypertensive Nephrosclerosis: Pathological Changes and Overlap with Diabetic Nephropathy.Cureus · 2025Review
- Evaluating the Effectiveness of Insulin Plus Oral Medications Versus Oral Anti-Diabetes Therapy Alone in Patients With Newly Diagnosed Type 2 Diabetes With Very High hbA1c and Acute Coronary Syndrome.Endocrinology, diabetes & metabolism · 2025Observational
- Elevated Triglyceride-Glucose Index as a Risk Stratification Marker for Diabetic Retinopathy in Type 2 Diabetes Mellitus: The Influence of Glycemic Control.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Telehealth for Integrated Cardiovascular and Diabetes Management: A Scoping Review.Journal of diabetes research · 2025Article
- Diabetes Management Based on the Phenotype and Stage of the Disease: An Expert Proposal from the AGORA Diabetes Collaborative Group.Journal of clinical medicine · 2024Review
- Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.The Lancet regional health. Western Pacific · 2024Article
- Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment.Journal of clinical medicine · 2024Article
- Cardiologists vs Endocrinologists in Glycemic Control for Coronary Artery Disease Patients with Type 2 Diabetes: A Cross-Sectional Study.Journal of multidisciplinary healthcare · 2024Article
- A comprehensiveFrontiers in pharmacology · 2024Review
- Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective.ClinicoEconomics and outcomes research : CEOR · 2024Article
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.Diabetes, obesity & metabolism · 2023Article
- The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.Advances in therapy · 2023Review
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.medRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that the multiple factors contributing to the pathogenesis of type 2 diabetes (T2D) confer an increased risk of developing cardiovascular disease (CVD). Although the relationship between hyperglycaemia and increased microvascular risk is well established, the relative contribution of hyperglycaemia to macrovascular events has been strongly debated, particularly owing to the failure of attempts to reduce CVD risk through normalizing glycaemia with traditional therapies in high-risk populations. The debate has been further fuelled by the relatively recent discovery of the cardioprotective properties of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Further, as guidelines now recommend individualizing glycaemic targets, highlighting the importance of achieving glycated haemoglobin (HbA1c) goals safely, the previously observed negative influences of intensive therapy on CVD risk might not present if trials were repeated using current-day treatments and individualized HbA1c goals. Emerging longitudinal data illuminate the overall effect of excess glucose, the impacts of magnitude and duration of hyperglycaemia on disease progression and risk of CVD complications, and the importance of glycaemic control at or early after diagnosis of T2D for prevention of complications. Herein, we review the role of glucose as a modifiable cardiovascular (CV) risk factor, the role of microvascular disease in predicting macrovascular risk, and the deleterious impact of therapeutic inertia on CVD risk. We reconcile new and old data to offer a current perspective, highlighting the importance of effective, early treatment in reducing latent CV risk, and the timely use of appropriate therapy individualized to each patient's needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.